Kedar Hastak, PhD
Senior Field Applications Scientist
Tuesday, September 29 | 12:20 PM Eastern
Enabling the Expansive Interrogation of a Tumor & Its Microenvironment from a Single Sample for Translational Research and Precision Medicine
- While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomic profiling.
- The traditional means of generating information relating to multiple biomarkers involves the use of several assay technologies from various sources which is not only impractical given the often limited quantity of tumor samples, but also due to complexities associated with the integration and interpretation of disparate reporting formats, and can be prohibitively costly.
- In this presentation, we’ll present our solution to these barriers, ImmunoID NeXT™, a universal cancer immunogenomics platform that consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor and its microenvironment, from a single sample.
- We will also talk about our diagnostic initiatives (NeXT Dx™) which support patient management, and biomarker-driven clinical trials and NeXT CDx™ a comprehensive companion diagnostic platform.